Greg Cima
Science and business reporter for 360Dx/GenomeWeb
Articles
-
2 weeks ago |
genomeweb.com | Greg Cima
NEW YORK – Starting with a molecular residual disease (MRD) test for early-stage breast cancer patients, Saga Diagnostics said that it is bringing to market a multi-cancer testing platform that targets patient-specific structural variants to determine whether treatments are working and detect recurrence months to years ahead of clinical signs.
-
2 weeks ago |
360dx.com | Greg Cima
NEW YORK – Starting with a molecular residual disease (MRD) test for early-stage breast cancer patients, Saga Diagnostics said that it is bringing to market a multi-cancer testing platform that targets patient-specific structural variants to determine whether treatments are working and detect recurrence months to years ahead of clinical signs.
-
3 weeks ago |
360dx.com | Greg Cima
NEW YORK – Canadian researchers have developed a point-of-care molecular blood test to quickly predict which patients in the emergency department or ICU are likely to develop sepsis within 24 hours.
-
3 weeks ago |
genomeweb.com | Greg Cima
NEW YORK – Canadian researchers have developed a point-of-care molecular blood test to quickly predict which patients in the emergency department or ICU are likely to develop sepsis within 24 hours.
-
1 month ago |
360dx.com | Greg Cima
NEW YORK – Agilent Technologies has been making changes to its supply chain, adjusting its pricing, and applying an ongoing restructuring program to mitigate the effects of US tariffs and retaliatory tariffs.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 72
- Tweets
- 149
- DMs Open
- Yes
RT @360DxNews: Meet Ravgen, the Little-Known Company Rattling NIPTs Biggest Players in Court. The firm alleges its competitors infringe its…
RT @360DxNews: UPDATE: FDA Allowed Problematic COVID-19 Tests on the Market Due to Agency's EUA Approach, HHS OIG Finds. In a report releas…
RT @360DxNews: Allergenis Seeks to Change Peanut Allergy Testing. Allergenis claims its assay results are more accurate than other first-li…